Cellectar BioSciences reports wider six-month loss and higher R&D spend
Cellectar BioSciences posted a net loss of about $12.6 million for the six months ended June 30, 2026.
Research and development expense rose 30% to about $7.57 million, driven by higher clinical and manufacturing costs tied to confirmatory and TNBC studies.
General and administrative expense fell 18% to about $5.43 million on lower professional fees, pre-commercialization spend, and personnel costs.
Cash totaled about $34 million at June 30, 2026; management said liquidity could run out beyond the second quarter of 2027 without added capital.
Phase 3 confirmatory work in Waldenstrom macroglobulinemia began in June 2026; a May financing provided about $35 million upfront with up to $105 million milestone-based.
CLRB•
